FI119415B - Paikalliseen lääkintään tarkoitettu, asikloviiria ja hydrokortisonia sisältävä farmaseuttinen koostumus - Google Patents

Paikalliseen lääkintään tarkoitettu, asikloviiria ja hydrokortisonia sisältävä farmaseuttinen koostumus Download PDF

Info

Publication number
FI119415B
FI119415B FI973243A FI973243A FI119415B FI 119415 B FI119415 B FI 119415B FI 973243 A FI973243 A FI 973243A FI 973243 A FI973243 A FI 973243A FI 119415 B FI119415 B FI 119415B
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
hydrocortisone
aciclovir
infections
infection
Prior art date
Application number
FI973243A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973243A0 (fi
FI973243A (fi
Inventor
Johan Georg Harmenberg
Ann Harriet Marg Kristofferson
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of FI973243A0 publication Critical patent/FI973243A0/fi
Publication of FI973243A publication Critical patent/FI973243A/fi
Application granted granted Critical
Publication of FI119415B publication Critical patent/FI119415B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FI973243A 1995-02-06 1997-08-06 Paikalliseen lääkintään tarkoitettu, asikloviiria ja hydrokortisonia sisältävä farmaseuttinen koostumus FI119415B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9500114 1995-02-06
SE9500114 1995-02-06
PCT/SE1996/000124 WO1996024355A1 (en) 1995-02-06 1996-02-02 Novel pharmaceutical combination
SE9600124 1996-02-02

Publications (3)

Publication Number Publication Date
FI973243A0 FI973243A0 (fi) 1997-08-06
FI973243A FI973243A (fi) 1997-08-06
FI119415B true FI119415B (fi) 2008-11-14

Family

ID=20396821

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973243A FI119415B (fi) 1995-02-06 1997-08-06 Paikalliseen lääkintään tarkoitettu, asikloviiria ja hydrokortisonia sisältävä farmaseuttinen koostumus

Country Status (30)

Country Link
US (2) USRE39264E1 (de)
EP (2) EP1419803B1 (de)
JP (2) JP4260220B2 (de)
KR (1) KR100431042B1 (de)
CN (1) CN1131034C (de)
AR (1) AR002030A1 (de)
AT (2) ATE262907T1 (de)
AU (1) AU716809B2 (de)
CA (1) CA2211389C (de)
DE (3) DE69632034T2 (de)
DK (1) DK0809498T3 (de)
DZ (1) DZ1966A1 (de)
ES (1) ES2214528T3 (de)
FI (1) FI119415B (de)
FR (1) FR10C0038I2 (de)
HK (1) HK1004368A1 (de)
HR (1) HRP960034B1 (de)
IL (1) IL116913A0 (de)
MA (1) MA23800A1 (de)
MY (1) MY119365A (de)
NO (1) NO314220B1 (de)
NZ (1) NZ301407A (de)
PT (1) PT809498E (de)
SA (1) SA96160590B1 (de)
SI (1) SI0809498T1 (de)
TN (1) TNSN96024A1 (de)
TW (1) TW438585B (de)
WO (1) WO1996024355A1 (de)
YU (1) YU49477B (de)
ZA (1) ZA96527B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
IT1287114B1 (it) * 1996-10-31 1998-08-04 Recordati Chem Pharm Composizioni farmaceutiche antierpetiche per applicatori topici, contenenti aciclovir
SE9803929D0 (sv) * 1998-11-18 1998-11-18 Medivir Ab Antiviral formulation
US7223387B2 (en) 1998-11-18 2007-05-29 Medivir Ab Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
FR2837102B1 (fr) * 2002-03-18 2004-10-08 Palbian Snc Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7618950B2 (en) * 2004-07-07 2009-11-17 Arigen Pharmaceuticals, Inc. Method for treatment and prevention of herpes zoster by topical application
WO2006105216A1 (en) * 2005-03-30 2006-10-05 Novartis Ag Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment
CA2604392A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
JP2009512677A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼタイプｉｖ阻害剤の組成物
FR2900577B1 (fr) * 2006-05-04 2008-09-12 Goemar Lab Sa Nouveaux medicaments pour les traitements contre le virus de l'herpes
EP2066661A2 (de) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP1958947A1 (de) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitoren für Phosphodiesterase Typ 4
CA2680625C (en) 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (de) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridinderivate als phosphodiesterasehemmer
EP2155209A4 (de) * 2007-04-26 2012-06-13 Univ Pennsylvania Dna-polymerase-inhibitorzusammensetzung und verfahren
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
US20090291895A1 (en) * 2008-05-23 2009-11-26 Wong Scott W Methods and Compositions for the Treatment of Inflammatory Diseases
US20110065655A1 (en) * 2009-09-17 2011-03-17 Karry Whitten Therapeutic composition to treat lesions caused by herpes simplex virus
CN102049050B (zh) * 2009-11-02 2014-06-18 重庆华邦制药有限公司 抗疱疹病毒感染的药物组合物
EP2489354A1 (de) 2011-02-18 2012-08-22 Vironova AB Pharmazeutische Formulierung enthaltend B220 zur topischen Behandlung von Herpes
ITMI20111747A1 (it) * 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
FR2983731B1 (fr) * 2011-12-07 2014-04-25 Univ Paris Descartes Emulsions topiques a base de melanges eutectiques d'anesthesiques locaux et d'acide gras
WO2014159731A1 (en) * 2013-03-13 2014-10-02 Nal Pharmaceuticals, Ltd A topical antiviral composition containing a local anesthetic and method of making the same
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
CN108853140A (zh) * 2018-07-18 2018-11-23 豆立忠 一种多药物模块软膏及其制备方法
WO2020036545A1 (en) * 2018-08-17 2020-02-20 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Phase stable topical composition comprising acyclovir and hydrocortisone
KR20220020911A (ko) 2019-06-14 2022-02-21 프로펠라 쎄라퓨틱스, 인크. 국소 아시클로버 제형 및 이의 용도
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
KR20230024280A (ko) * 2020-05-11 2023-02-20 르비어, 인크. 바이러스 감염을 치료하기 위한 조성물 및 방법(compositions and methods for treating viral infections)
CN112704154A (zh) * 2020-12-24 2021-04-27 中国人民解放军66399部队 一种用于治疗宠物猫疱疹病毒的营养膏
US11951082B2 (en) * 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317384A (en) 1964-06-08 1967-05-02 Upjohn Co Treatment of topical viral infections with glucocorticoids and nucleosides
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0594223B1 (de) * 1985-09-17 2000-03-01 The Wellcome Foundation Limited Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
US4942031A (en) 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
US5023090A (en) 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
AU636255B2 (en) * 1990-11-05 1993-04-22 Arthropharm Pty Ltd Use of a topical formulation for the treatment of viral infections and neoplastic disorders
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
GB9315755D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
DZ1965A1 (fr) * 1995-02-06 2002-07-17 Astra Ab Composition pharmaceutique nouvelle.
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
HRP960034A2 (en) 1997-10-31
YU49477B (sh) 2006-05-25
EP1419803A2 (de) 2004-05-19
JP2007284452A (ja) 2007-11-01
JP4260220B2 (ja) 2009-04-30
FI973243A0 (fi) 1997-08-06
NO314220B1 (no) 2003-02-17
TW438585B (en) 2001-06-07
AR002030A1 (es) 1998-01-07
SA96160590B1 (ar) 2005-10-05
EP0809498A1 (de) 1997-12-03
SI0809498T1 (en) 2004-12-31
CN1131034C (zh) 2003-12-17
ZA96527B (en) 1996-08-06
JPH11506417A (ja) 1999-06-08
FR10C0038I2 (de) 2011-04-29
FR10C0038I1 (de) 2010-10-15
CA2211389A1 (en) 1996-08-15
IL116913A0 (en) 1996-05-14
DK0809498T3 (da) 2004-05-10
CA2211389C (en) 2007-11-20
HRP960034B1 (en) 2002-02-28
ES2214528T3 (es) 2004-09-16
EP1419803A3 (de) 2004-06-09
US6337324B1 (en) 2002-01-08
WO1996024355A1 (en) 1996-08-15
DZ1966A1 (fr) 2002-10-15
TNSN96024A1 (fr) 2005-03-15
FI973243A (fi) 1997-08-06
HK1004368A1 (en) 1998-11-27
DE122010000032I1 (de) 2010-10-21
EP1419803B1 (de) 2009-01-21
DE69632034D1 (de) 2004-05-06
ATE262907T1 (de) 2004-04-15
NO973612L (no) 1997-09-26
CN1179718A (zh) 1998-04-22
DE69632034T2 (de) 2004-10-14
AU4682196A (en) 1996-08-27
NO973612D0 (no) 1997-08-05
AU716809B2 (en) 2000-03-09
MY119365A (en) 2005-05-31
YU7296A (sh) 1998-08-14
EP0809498B1 (de) 2004-03-31
KR100431042B1 (ko) 2004-06-16
DE69637828D1 (de) 2009-03-12
ATE421358T1 (de) 2009-02-15
MA23800A1 (fr) 1996-10-01
PT809498E (pt) 2004-06-30
KR19980701959A (ko) 1998-06-25
USRE39264E1 (en) 2006-09-05
NZ301407A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
FI119415B (fi) Paikalliseen lääkintään tarkoitettu, asikloviiria ja hydrokortisonia sisältävä farmaseuttinen koostumus
EP0109234B1 (de) Zusammensetzungen mit Gehalt an Interferon und ihre therapeutische Anwendung
DE60036862T2 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge
CN101460158A (zh) 用于治疗和/或预防唇部单纯疱疹感染的局部用喷雾组合物
EP0119757B1 (de) Guanin-Derivate, diese enthaltende Zusammensetzungen und ihre antivirale Wirkung
JP2008088189A (ja) 潜伏ヘルペスウイルス感染の治療および予防のためのアミノプリン抗ウイルス剤の使用
EP0502048B1 (de) Verwendung von kaffein bei der behandlung von herpes-simplex-virusinfektionen
Park et al. Iontophoretic application of adenine arabinoside monophosphate to herpes simplex virus type 1-infected hairless mouse skin
US4902678A (en) Anti-viral compositions
HU226793B1 (en) Use of nucleoside analogs and cyclosporin a in the manufacture of combined preparation against herpes simplex virus infections
JPH0138770B2 (de)
US20110070321A1 (en) Method and Composition for Cutaneous Treatment of Herpes Simplex Infections
EP0082667A1 (de) Pharmazeutische Zusammensetzungen
KR20180077138A (ko) Ｎ-메타노카르바티미딘(n-mct)을 사용한 대상포진의 치료 방법
Jaffe et al. Cidofovir Therapy for Cutaneous Viral Infections
JPH09506883A (ja) 薬 剤
JP2012184252A (ja) 潜伏ヘルペスウイルス感染の治療および予防のためのアミノプリン抗ウイルス剤の使用
MXPA97004336A (en) Use of antiviral agents for the treatment and prophylaxis of latent infections of herpesvi

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: MEDIVIR AB

Free format text: MEDIVIR AB

FG Patent granted

Ref document number: 119415

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Free format text: SPC C20100008

Spc suppl protection certif: C20100008

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 367

Extension date: 20210202

MA Patent expired